Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Theranostics
Song H, Yang P, Huang P, Zhang C, Kong D, Wang W.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2019
Cancer Research
Immunology
No items found.
Key Finding
The findings indicate that the polypeptide hydrogel can be used as an effective sustained delivery platform for vaccines and immune checkpoint inhibitors, providing an advanced combinatorial immunotherapy approach for cancer treatment.
Countstar Connection
For the study's cell samples, researchers obtained cell-count measurements with a Countstar instrument during quality assessment for the cancer-model experiments.
